Generic drugs now account for more than 60% of all prescriptions filled in the US, and more than $60 billion worth of drugs face US patent expiration by 2011. 

Use this report to build a counter-generics strategy that includes long-term, R&D-based lifecycle planning (such as new formulations and next-generation drugs) as well as frontline tactics (such as litigation and counter-promotion) -- and understand how companies launch authorized generics and attempt OTC switches

Explore primary data for a comprehensive look at current counter-generics defense:

• Investigate strategies, investments and results for seven brands
• Benchmark your efforts against timelines, investment levels, and past-and-future use of critical lifecycle management and counter-generics options:
  • New formulation launches
  • Defensive pricing changes
  • Counter-promotion
  • Approval for new indications
  • Next-generation product launches
  • Patent litigation
  • Authorized generics negotiations
  • Launches through generics subsidiaries
  • Pediatric trials and six-month exclusivity
  • OTC switching
• Compare headcounts dedicated to counter-generics preparation over the life of a brand

 

More Cutting Edge Information Reports: